The following blog post is by Tom Krohn. Tom is the Chief Development Officer for TrialReach and is responsible for business development including clinical trial sponsor relationships, patient advocacy groups and research institutions. He has 25 years of experience across different sectors in health including large pharma, hospital & retail pharmacy, and the developing world. Most recently, Tom led the Clinical Open Innovation team at Eli Lilly with a focus on patient engagement, open data and business transformation. Tom is passionate about serving patients from their point-of-view while building sustainable and highly effective organizations.
Everyone Has a Story
Everyone has a story. You. Me. Innovation.
About four years ago, a small group of Lilly employees started work on open innovation with a focus on improving public information to accelerate medical innovation. Barry Crist and I wrote a whitepaper that outlined a vision for clinical knowledge generation becoming participatory for all in the clinical research ecosystem, especially patients. Participatory—that is the essence of an open network. It is at the core of open innovation.
With executive sponsorship and a case for action, we took these ideas and developed an open API which launched in 2012. We put Creative Commons copyleft licensing on the API to remove the friction that is the norm of the life-science industry. Then, open innovation happened.
Click the image to view the full interactive map.
Did you know that in 2013 approximately 382 million people worldwide were living with diabetes? Prevalence is third highest in the U.S., where 22.1 million people were living with diabetes in 2011. That’s an increase of 39.5 percent since 2004. Though diabetes is common and rising in prevalence, individual awareness is low, both internationally and in the U.S. Awareness is key to preventing and managing diabetes. Internationally, 46 percent of diabetes cases are undiagnosed. In the U.S., one in four diabetics do not know they have diabetes. And only one in 10 of the 86 million pre-diabetic U.S. adults know about their condition. Without weight loss and moderate physical activity, 15 to 30 percent of those with pre-diabetes will develop Type 2 diabetes within five years. Once people become diabetic, they are at higher risk of serious health complications and their medical expenses become twice as high. More…
Tyler Trueg is a project lead on the Patients 2 Trials Consortium, a collaboration among Lilly, Novartis and Pfizer aimed at helping patients match to clinical trials. He joined Lilly as part of the Lilly’s Visiting Scientist Fellowship, a program which allows doctoral graduates the ability to experience the drug development process and apply their expertise in a focused area within the organization.
Tyler’s experience in pharmacy and business, along with a passion for technology and disruptive innovation makes him a great addition to the Lilly COI team. While he is a scientist at heart, his entrepreneurial spirit drives him to find new ways to bring the patient’s perspective into clinical trial design. His overall mission is to help clinical trial teams better connect with patients through the use of technology and community engagement. You can follow him on Twitter @tylertrueg.
hGraph: patient + clinician looking together by Kelly Mansfield is licensed under CC by 2.0
ePatients—patients who are well-informed and empowered by digital technology and see themselves as equal partners with their doctors and healthcare providers—are on their way to becoming more the norm than the exception. For example, according to a recent Pew Research study, 72 percent of Internet users said they had looked up health information in the past year.
Another often-quoted statistic about the current state of clinical trials tells us that only 16 percent of cancer patients surveyed are aware that clinical trials are an option. This could indicate that we are missing opportunities to increase awareness about clinical trials through digital technology and online resources. In a time where 30 percent of trials never get off the ground because they fail to enroll enough patients, we can’t afford to miss these opportunities any longer. Bringing information about clinical trials to ePatients is important in expanding healthcare options and getting better treatments to the public faster.